Pipeline

MAXONA Pharmaceuticals is committed to applying its intellectual property and unique expertise to develop patient-centric therapies that are efficacious, safe, trusted and clinically proven.

Anticipated Pipeline Overview

(1) Development status for chronic indications is pending completion of longer term (6-9 months) preclinical toxicology studies.

Additional development platforms for MAX-001 include chronic pain and additional dosage forms and indications.

Next Generation Therapies